Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Biotechnology

Healthcare
$95.05 +0.77%

+$0.42 today

Market cap
$7.47B
Beta
0.12
P/E (TTM)
57.2
EPS (TTM)
$0.95
52W Low $26.27High $59.87

Volume 0.33M

Average 0.66M

KNSA Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA

Other Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other non-current liabilities rises 267.3% from a year ago

Other non-current liabilities stood at $34.02M at the end of Q2 FY2026, up 267.3% from a year earlier and up 34.4% from the prior quarter. Over 3 fiscal years it compounded at +116.0% a year.

Context

  • Other non-current liabilities amounted to 3.8% of total assets at the end of Q2 FY2026, up 2.4 pp from a year earlier.
  • Other non-current liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether other non-current liabilities keeps rising in the next quarterly balance sheet after a +267.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$34.02M+34.4% QoQ
Last fiscal yearDec 2025
$18.52M+916.0% YoY
Year agoJun 2025
$9.26M+267.3% since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+267.3%——
1 year+916.0%——
3-year CAGR+116.0%——
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
18.52M USD
Year-over-year change
+916.0%
4-year CAGR
+187.8%

Other Non-current Liabilities vs competitors

How KNSA compares with its peers on the latest reported figures

  • KNSA's Jun 2026 other non-current liabilities of $34.02M is the highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +267.3% is the highest of 5, against a peer median of +8.0%.
  • Other non-current liabilities amounts to 3.8% of total assets for KNSA, versus a peer median of 0.0%.
KNSA Competitors Peer median
Other Non-current Liabilities for KNSA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KNSAKiniksa Pharmaceuticals, Ltd.Jun 2026$34.02M +267.3%+116.0%3.8%
NRIXNurix Therapeutics, Inc.Aug 2026$23.38M ——2.0%
AVTXAvalo Therapeutics, Inc.Mar 2026$17.52M +79.9%+28.2%17.5%
ACRSAclaris Therapeutics, Inc.Mar 2026$11M -64.0%-31.8%5.5%
SYRESpyre Therapeutics, Inc.Sep 2026$8.05M +149.2%—0.7%
ORKAOruka Therapeutics, Inc.Sep 2026$0 ——0.0%
IMVTImmunovant, Inc.Sep 2026$0 ——0.0%
DNTHDianthus Therapeutics, Inc.Jun 2026$0 ——0.0%
ANABAnaptysBio, Inc.Mar 2026$0 -100.0%-3.2%0.0%
PHARPharming Group N.V.Mar 2026$0 ——0.0%
Peer median (excluding KNSA) $0+8.0%-3.2%0.0%

Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents122.47M122.72M107.95M183.58M165.6M
Short-term Investments59.73M67.89M98.42M60.05M248.48M
Net Receivables3.99M20.32M21.27M41.72M15.59M
Inventory3.68M21.6M31.12M26.36M54.9M
Other Current Assets010.54M17.54M20.08M42.61M
Total Current Assets196.45M243.06M276.3M331.8M527.18M
Property, Plant & Equipment (Net)8.38M7.04M12.67M11.04M11.75M
Goodwill00000
Intangible Assets19.25M18.25M17.25M16.25M15.25M
Long-term Investments00000
Tax Assets0185.5M219.28M211.15M198.15M
Other Non-current Assets8.72M5.82M827K10.32M11.31M
Total Non-current Assets36.35M216.61M250.03M248.75M236.46M
Total Assets232.8M459.67M526.32M580.55M763.63M
Account Payables1.87M7.9M8.25M2.04M2.03M
Short-term Debt00002.99M
Tax Payables00000
Deferred Revenue00307K031.81M
Other Current Liabilities1.54M16.97M36.91M33.12M102.36M
Total Current Liabilities44.82M47.07M63.67M100.62M139.18M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)012M11.95M31.81M31.81M
Other Non-current Liabilities270K1.84M1.86M1.82M18.52M
Total Non-current Liabilities2.94M16.46M23.82M41.5M56.84M
Total Liabilities47.76M63.52M87.48M142.12M196.03M
Common Stock18K19K20K20K21K
Retained Earnings(675.4M)(492.03M)(477.95M)(521.14M)(462.14M)
Accumulated OCI(66K)44K6K(163K)(25K)
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity185.04M396.15M438.84M438.44M567.61M
Total Debt6.05M5.92M12.26M9.86M9.5M
Net Debt(116.42M)(116.8M)(95.7M)(173.73M)(156.1M)

Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Intrinsic Alpha fair value

Locked

Current Price

$95.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.